I look forward to seeing all of you at our Smilow Cancer Hospital Town Hall meeting, which has been rescheduled to Wednesday, March 2 at 11:30 AM in the auditorium at 55 Park Street.
Abe Lopman, Cathy Lyons, Peter Marks, and I will be sharing the latest information on goals and operations at Smilow. We also welcome your suggestions and comments and look forward to hearing from you. Please mark your calendars and plan to attend.
YCC Annual Retreat
Please save the date for our annual scientific retreat on Tuesday, May 31, at Yale's West Campus.
We will host members of the UCL Cancer Program and invite members of Yale Cancer Center to present their latest research findings. My goal is to make the meetings as interactive as possible, and we welcome your input and suggestions.
Research in the News
Scientists Synthesize Anticancer Agent
A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.
Led by chemist Seth Herzon, the group managed to create lomaiviticin aglycon for the first time, opening up new avenues of exploration into novel chemotherapies that could target cancer stem cells, thought to be the precursors to tumors in a number of different cancers including ovarian, brain, lung, prostate, and leukemia.
In addition to lomaiviticin aglycon, Herzon's team also created smaller, similar molecules that have proven extremely effective in killing ovarian stem cells, explained Gil Mor, MD, PhD, a member of Yale Cancer Center who is collaborating with Herzon to test the new class of molecules' potential as a cancer therapeutic.
Lynn Tanoue, MD, Professor of Internal Medicine, Pulmonary and Critical Care, and Co-Director of the Thoracic Oncology Program, will be awarded The Connecticut Thoracic Society Award for dedication and service to the Connecticut Thoracic Society and the field of pulmonary medicine. Dr. Tanoue will receive the honor at the annual Breath of Spring Gala on April 8 in Simsbury.
Michele Dingus has been promoted to an Accountant (II) position in the Cancer Center.
Liz Vastakis will be leaving Yale Cancer Center after 11 years in the medical oncology business office to take an accounting position in Microbial Pathogenesis.
All inquiries should be directed to Jennifer Mulligan until Liz's position has been filled.
A Multi-Center, Placebo-Controlled, Randomized Pilot Study of the Effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and HCC Treated with Ablative Therapy and/or Transarterial Chemoembolization
A Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-up of Select GOG-0199 Study Participants
A Dose Finding and Phase II Study of AZD6244 (Hyd-Sulfate) in Combination with Irinotecan in 2nd Line Patients with K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer
The Samuel Waxman Cancer Research Foundation (SWCRF)
"Reprogramming the Cancer Cell" Request for Proposals
The SWCRF provides ongoing support through collaborative grants, the sharing of information, reagents, technologies and ideas, and the organization of international conferences, to create an Institute Without Walls.
Investigators of the Foundation have long been interested in differentiation therapy of cancer- the notion that the cancer cell can be re-programmed to re-acquire aspects of normal cell differentiation including terminal cell division and programmed cell death. In 2011, the Foundation will offer several grants of up to $100,000 per year to fund novel research along these lines.
Yale Cancer Center can submit one proposal. For consideration to apply, please submit a one page description of your research project and your CV to Dan DiMaio, MD, PhD and Jan Zulkeski by Friday, February 18.
The Damon Runyon Cancer Research Foundation invites institutions to nominate candidates to apply for its Clinical Investigator Award program, which protects and cultivates those promising young physician-scientists willing to devote their careers to the development and application of new diagnositc approaches and therapeutic strategies for cancer and cancer prevention through clinical investigation. The award will provide financial support for the investigator and an allowance for research costs. In addition, the Foundation will retire up to $100,000 of any medical school debt owed by the awardee.
If interested, please submit a letter of intent and CV to Chad Ellis by Thursday, February 10 at noon for consideration.
Palliative and End of Life Care Education Programs
The State of Connecticut, Department of Public Health is seeking proposals from public and private organizations and community-based agencies to provide palliative and end-of-life care education/certification programs for nursing and/or social work.
The intent of the Request for Proposal is to implement strategies that will meet the goal and objectives of the Connecticut Cancer Plan 2009-2013 related to palliative and hospice care:Ensure that high quality and hospice care services are available and accessible to all Connecticut residents.
A total of up to $60,000 of state funds is available to support this project.
Funding will begin approximately July 1, 2011 through June 30, 2013, subject to the availability of funds and satisfactory performance.
Enhancing Patient-Provider Communication With the Electronic Self-Report Assessment for Cancer: A Randomized Trial.
Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R.
J Clin Oncol. 2011 Jan 31.
Learn More >>
First Use of Intravenous Chemotherapy Cancer Treatment: Rectifying the Record.
Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy: in regard to gondi v, et Al. (Int j radiat oncol biol phys 2010;78:1244-1252).
Knisely JP, Yu JB.
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):957-8.
Learn More >>
Hematology in 2010: New therapies and standard of care in oncology.